



LIMITED REVIEW REPORT

To
M/s **SAAMYA BIOTECH (INDIA) LIMITED**
Hyderabad

We have reviewed the accompanying statement of unaudited financial results of M/s **SAAMYA BIOTECH (INDIA) LIMITED** for the period ended 31st December 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14.02.2017

For **M M REDDY & CO.,**
Chartered Accountants
Firm Registration No.010371S




M Madhusudhana Reddy
Partner
Membership No. 213077

¹ The Accounting Standards notified pursuant to Companies (Accounting Standards) Rules, 2006 and/ or Accounting Standards issued by Institute of Chartered Accountants of India.



Saamya Biotech (India) Ltd.

CIN: L24239AP2002PLC039449

February 14, 2018

To

Corporate Relations Department,
BSE LTD,
P J Towers,
Dalal Street,
Mumbai - 400001.

Sirs,

Sub: Q3 Unaudited Financial Results – Reg...

Ref: Scrip Code – 532905

Please find herewith attached Un-audited financial results for the first quarter ending 31th December 2017 along with Limited Review Report. The Board Meeting Commenced at 4 PM and concluded at 5:15 PM. Please take on record the same.

Thanking You,

For SAAMYA BIOTECH (INDIA) LIMITED

G. Hanumantha Reddy

Director



Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604.
Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com

Regd. Office: Suite 104-106. Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241
Fax: +91-40-2339 5214 e-mail : saamyaindia@saamyabiotech.com



Saamyabiotech (India) Ltd.

SAAMYA BIOTECH (INDIA) LTD						
Statement of Un-Audited Results for the Quarter ended 31.12.2017						
S.No.	Particulars	Quarter Ended			Nine Months Ended	
		31.12.2017 Un-Audited	30.09.2017 Un-Audited	31.12.2016 Un-Audited	31.12.2017 Un-Audited	31.12.2016 Un-Audited
I.	Revenue from Operations	-	-	-	-	-
II.	Other Income	-	-	-	-	-
III.	Total income (I+II)	-	-	-	-	-
IV.	Expenses					
	(a) Cost of Materials consumed	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and	-	-	-	-	-
	(d) Employee benefits expense	0.48	0.53	2.49	1.57	7.47
	(e) Finance Cost	-	-	-	-	0.74
	(f) Depreciation and amortisation expense	-	-	22.50	-	67.50
	(h) Other expenses	0.25	0.25	0.27	0.75	7.24
	Total Expenses	0.73	0.78	25.25	2.32	82.21
V.	Profit / (Loss) before and exceptional items and Tax (III-IV)	(0.73)	(0.78)	(25.25)	(2.32)	(4,112.90)
VI.	Exceptional Items	-	-	-	-	-
VII.	Profit / (Loss) from before tax (V-VI)	(0.73)	(0.78)	(25.25)	(2.32)	(4,112.90)
VIII.	Tax expense					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	51.91
IX.	Net Profit / (Loss) after Tax (VII-VIII)	(0.73)	(0.78)	(25.25)	(2.32)	(4,164.81)
X.	Other Comprehensive Income					
	Items that will not be reclassified to Profit or Loss	-	-	-	-	-
	Items that will be reclassified to Profit or Loss	-	-	-	-	-
XI.	Total Comprehensive Income	(0.73)	(0.78)	(25.25)	(2.32)	(4,164.81)
XII.	Paid-up equity share capital (Face Value of Rs. 10/- per share)	2,488.25	2,488.25	2,488.25	2,488.25	2,488.25
XIII.	Earnings Per Equity Share of face value of Rs.10/- each)					
	a) Basic & Diluted (In Rs)	(0.00)	(0.00)	(0.10)	(0.01)	(16.74)

Date: 14.02.2018
Place: Hyderabad



For SAAMYA BIO TECH PRIVATE LIMITED

Dr. Y. Manivardhan Reddy
Dr. Y. Manivardhan Reddy
Managing Director


NOTES:

- The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.02.2018
- The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017, and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. The Ind-AS Compliant Standard/one Financial results for the corresponding quarter ended Dec 31, 2016 have been stated in terms of SEBI Circular dated July, 05, 2016.
- Reconciliation of results between previously reported (referred to as "Previous GAAP") and Ind-AS for the corresponding quarter and Nine Months ended December 31, 2016 is as under;

Particulars	Quarter ended 31st Dec, 2016	Nine Months Ended 31th Dec, 2016
Net Profit/(Loss) after Tax under Indian GAAP	-25.25	-82.21
Details of Ind-As Adjustments		
Impairment of Fixed Assets	-	-
Other	-	-
Net Profit for the period as per Ind-AS	-25.25	-82.21
Add: Other Comprehensive Income	-	-
Total Comprehensive Income for the Period as per Ind-AS	-25.25	-82.21

- The results are also available on the website of the Company www.saamyabiotech.com
- The Company is not operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments"

Station: Hyderabad
Date: 14.02.2018



For SAAMYA BIO TECH PRIVATE LIMITED

Dr. Y. Manivardhan Reddy
Dr. Y. Manivardhan Reddy
Managing Director

Corporate Office: Plot No. 391- D, Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604, Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Website: www.saamyabiotech.com

Regd. Office: Suite 104-106, Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241 Fax: +91-40-2339 5214 e-mail : saamyaindia@saamyabiotech.com